This book, the proceedings of Falk Symposium 163 Chronic Inflammation of Liver and Gut, held in Hangzhou, P.R. China, on March 14--15, 2008, presents the most recent progress in chronic inflammatory diseases of liver and gut. It focusses on molecular understanding, the therapeutic state of the art and future options of treatment.

The first part of the book concentrates on basic and clinical aspects of IBD. Chapters demonstrate the role of the immune system, genetic factors and the intestinal microflora in IBD, and give an evidence-based update on the current diagnostic and therapeutic options and present future perspectives for the management of IBD. The second part is devoted to chronic liver diseases with particular focus on the liver as an immune organ, treatment strategies of viral hepatitis and liver fibrogenesis. The final part deals with basic and clinical aspects of liver cirrhosis, hepatocellular carcinoma and liver transplantation. The book concludes with an outlook on therapeutic options of hepatic stem cells. Throughout, international experts from the USA, the People s Republic of China and Europe contribute their experience in different aspects of the mechanisms and management of chronic inflammatory diseases of liver and gut. "

Hepatitis C virus (HCV), a major causative agent of chronic liver disease, is spread throughout the world and around 170 million people are persistently infected. In this volume, world-leading experts in the field of HCV research have compiled the most recent scientific advances to provide a comprehensive and very timely overview of the various facets of HCV. The book starts with a discussion of the possible origin of HCV and its spread among the human population. The focus of the subsequent chapters is on available cell culture and in vivo models before shifting to the molecular and cellular principles underlying the viral replication cycle. These chapters are complemented by insightful descriptions of the innate and adaptive immune responses to HCV as well as the virus-associated pathogenesis. Finally, the development of antiviral therapies, which is closely linked with progress in basic research, and the implementation of those therapies into present and future daily clinical practice are highlighted.

Hepatitis C in Developing Countries: Current and Future Challenges explores the current state of HCV in several countries, including Africa, Asia and South America. It maintains a dedicated focus on the epidemiology, clinical patterns, virologic diversity, coinfections, natural history and progression, complications, and response to standard of care (SOC) pegylated interferon and ribavirin therapy of HCV with recommendations specific to middle and low income countries. Readers will find detailed information on the burden of HCV infection from a global health and economic perspective, along with data from multicenter trials on DAAs that have enrolled patients infected with HCV non-genotype 1.

Cirrhosis from hepatitis C (HCV) is now the most common indication for liver transplant (LT) in the U.S., but between 2004 and 2013, new LT listings for NASH increased by 170%. Unfortunately, fibrosis progression leading to cirrhosis, liver cancer, and liver decompensation continues to occur after transplantation. Once cirrhosis and decompensation are evident, patient survival is poor and repeat LT is considered to improve outcomes. Therefore, the never-ending thirst for new approaches in the management of patients pre- and post-transplant has led to a very promising future in transplantation, thought there is much to learn to achieve better patient outcomes. This issue of Clinics in Liver Disease addresses the core areas to achieve better patient outcomes, with articles devoted to coagulopathy before liver transplant, challenges in renal failure before LT, LT for acute alcoholic hepatitis, LT in the pregnant patient, bariatric surgery and LT,and MELD Scores in prioritization of LT, to name a few. Readers will place a high value on the current state of liver transplantation in this issue.

Dr. Younossi is a highly-esteemed expert in Hepatitis C Virus (HCV), and for the first time in Clinics in Liver Disease, he has compiled articles that specifically address the extrahepatic manifestation of HCV. Articles are specifically devoted to the following topics: Hepatitis C: A Systemic Disease; Rheumatologic Manifestations of HCV; Cardiovascular Manifestations on HCV; Metabolic Manifestations of HCV (DM, Dyslipidemia); Renal Manifestations of HCV; Lymphoproliferative Disorders Associated with HCV; Depression and HCV; Neurologic Manifestations of HCV; Non-HCC Malignancies in HCV; Dermatologic Manifestations of HCV; Fatigue and Patient-reported Outcomes in HCV; Economic Burden of HCV; and Endocrine Manifestations of HCV (non-dabetes). The thorough coverage of systemic issues will give clinicians the information they need to effectively manage the HCV patient with other health issues.

The Liver: Oxidative Stress and Dietary Antioxidants takes a novel approach to the science of oxidative stress in liver disease by recognizing that diseases are multifactorial and oxidative stress is a single component. It highlights oxidative stress in relation to other processes, such as apoptosis, cell signaling and receptor mediated responses, and includes the therapeutic usage of natural antioxidants in the diet and food matrix, along with coverage of pharmacological and natural agents designed to counteract oxidative stress. Written for research scientists, gastroenterologists, food scientists, hepatologists and physicians, this trans-disciplinary guide will help advance medical sciences and enable new preventative and treatment strategies.

Dr. Lefkowitch has created a primer on liver pathology for the gastroenterologist that provides depth of clinical coverage in an area not typically covered in depth for gastroenterologists. This issue will provide state-of-the-art reviews in the areas of NAFLD, liver biopsy, liver pathology, hepatitis, and genomics. Articles are specifically devoted to IgG4-related disease and the liver; current concepts in pediatric NAFLD; evaluation of the pediatric liver biopsy; hepatocellular adenomas: morphology and genomics; drug-induced liver injury: the hepatic pathologist's approach; liver pathology in alpha-1-antitrypsin deficiency; immunohistochemistry in the diagnosis of hepatocellular carcinoma; HIV infection, antiretroviral therapy and liver pathology; autoimmune hepatitis overlap syndromes and liver pathology; current perspectives on the pathology of hepatocellular carcinoma and its variants; hepatitis E virus and the liver: clinical settings and liver pathology; hepatic progenitor cells; and cholangiocarcinoma: current genomics and pathology, to name a few.

Control of Urea Synthesis and Ammonia Detoxification.- Brain Metabolism in Hepatic Encephalopathy and Hyperammonemia.- Ammonia Metabolism in Mammals: Interorgan Relationship.- Clinical Manifestations and Therapy of Hepatic Encephalopathy.- Nutritional Considerations in Patients with Hepatic Failure.- Do Benzodiazepine Ligands Contribute to Hepatic Encephalopathy?.- Effects of Hyperammonemia on Neuronal Function: NH4+, IPSP Cl-Extrusion.- Activation of NMDA Receptor Mediates the Toxicity of Ammonia and the Effects of Ammonia on the Microtubule-Associated Protein MAP-2.- Modulation of the Exocytotic Release of Neurotransmitter Glutamate by Protein Kinase C.- Controls of Cerebral Protein Breakdown.- Two Different Families of NMDA Receptors in Mammalian Brain: Physiological Function and Role in Neuronal Development and Degeneration.- Glanglioside GM1 and its Semisynthetic Lysogangliosides Reduce Glutamate Neurotoxicity by a Novel Mechanism.- Contributors.

An easy to follow step-by-step guide to the most useful surgical skills from knot tying to simple procedures. Illustrated with colour photographs and video clips to demonstrate techniques, this book makes these practical skills as clear and easy to follow as possible. Including coverage of surgical instruments, wound management and suturing, and minor surgical procedures, it also explains how to use these essential surgical skills to make the most of a surgical placement. Healthcare students or junior professionals undertaking a placement in surgery or emergency medicine will feel confident and capable, and will be able to take an active role in surgical placements. Learning basic surgical skills is important for such placements, as well as for undertaking exams such as the Membership of the Royal College of Surgeons (MRCS).

Cellular therapy with liver stem cells and their progeny, including bone marrow cells, is a promising new approach that will contribute significantly to the treatment of liver diseases. The existence of the liver stem cell had long been debated, but it is now generally accepted that the liver contains cells with stem-like properties and that these cells can be activated to proliferate and differentiate into mature hepatocytes under certain conditions. There is also a substantial body of evidence to suggest that oval cells are involved in liver regeneration as they differentiate into hepatocytes and biliary cells. This book is a collection of work on stem cell and liver regeneration, initially delivered at the 14th Yamaguchi (Japan) Symposium on Liver Disease. Its nine chapters present the most recent data about basic and clinical research in hepatology in Japan and other countries, providing a valuable resource for researchers and practitioners alike.

In 1992, the Falk Symposium No. 70 dealt with the topic Immunology and Liver'. At that time basic mechanisms of immunology as well as immunopathogenetic mechanisms in viral and autoimmune liver diseases were discussed. Now, 7 years later, the Falk Symposium No. 114, held in Basel, Switzerland, October 20-21 1999 (Part I of the Basel Liver Week 1999), focused on immunology in autoimmune liver diseases. In the first section basic mechanisms of autoimmunity are presented, including the relevance of superantigens and the role of apoptosis. A further topic is the latest developments concerning animal models for autoimmune diseases. Recently the International Autoimmune Hepatitis Group newly defined and reclassified the syndrome of autoimmune hepatitis. Autoimmune hepatitis is now identified and studied in all parts of the world, including Asia and South America. A special variant of autoimmune hepatitis was identified as one organ manifestation of the autoimmune polyendocrine syndrome type 1, a genetic disease caused by mutations in a single transcription factor. Drug- and hepatitis-virus induced immune mediated liver diseases may serve as models for nonhepatic immune mediated disorders. DNA technology has increased our knowledge of the immunogenetic background of autoimmune liver diseases. Among the cholestatic immune mediated liver diseases, significant progress has been made concerning primary biliary cirrhosis, in particular regarding the identification of mitochondrial antigens and the characterisation of the immune reactions directed at them. The involvement of infectious agents in PBC as well as the definition of overlap syndromes is a particular focus for basic and clinical research in this area. Concerning the therapy of autoimmune liver diseases, corticosteroids and azathioprin remain the state of the art for autoimmune hepatitis, while bile acids have become well established in treatment of primary biliary cirrhosis as well as primary sclerosing cholangitis. New drugs in the future will include topical steroids such as budesonide and new immunosuppressive agents like mofetil/mycophenolate. Liver transplantation is the treatment of choice for end stage liver diseases; all autoimmune liver diseases are among the best candidates for liver transplantation. Hopefully, new therapeutic strategies based on the results obtained from experimental models will become everyday clinical practice in the next decade. Therefore this symposium concludes with a discussion.

The only resource of its kind, this is a concise, practical guide to GI and Liver Disease that delivers current information on diagnosing, managing, and treating common GI and liver disorders, along with liver transplant guidelines. Written for nurses, nurse practitioners, and physician assistants in varied specialties, it fills a gap in information needed by primary and acute care professionals who are the chief caretakers for GI and liver patients. This guide delivers recent important treatment advances that have revolutionized GI and liver care, and provides guidance for seeking expert advice or urgent/emergent care for more complex cases. An outstanding feature is the prominently displayed Fast Facts in a Nutshell highlighting key takeaway points at a glance. The resource reviews common GI symptoms and disorders from irritable bowel disorders (including key differences between Crohn's disease and ulcerative colitis) to gallstones and GERD. A section on liver disease describes essential liver functions, reviews liver function tests, and addresses commonly and less commonly seen liver disease diagnoses. Complications of cirrhosis are examined to assure prompt recognition of these potentially deadly symptoms. Additionally, the book addresses liver transplantation with comprehensive attention to the evaluation process, organ donation/allocation, and post-transplant care for donor and recipient alike. Each chapter includes an overview, significant laboratory or imaging findings, treatment options, expected outcomes, and "Fast Facts in a Nutshell. An additional feature is the provision of IDC-10 codes for billing and reimbursement. Key Features: Provides speedy access to current information on diagnosing managing, and treating common GI and liver disorders for front-line professionals Includes comprehensive review of the liver, abnormal liver function tests (LFTs), and transplantation Reflects up-to date information on the latest treatment guidelines for gastrointestinal and liver disease, including celiac disease and Hepatitis C Addresses common gastrointestinal diseases and guidelines for treatment as outlined by ACG Discusses current liver disease management and guidelines for treatment as outlined by AASLD

This volume contains the proceedings of the Falk Workshop on Bile Acids in Hepatobiliary Disease, which took place at the Royal Society of Medicine (RSM) in London, UK, on 29-30 March 1999, and was held in association with the Section of Measurement in Medicine at the RSM. The main interest in bile acid therapy has been recently in cholestatic liver disease. The proceedings of the workshop not only discusses this, but moves on to examine its possible use in alcoholic liver disease, and moves back to re-examine its role in biliary disease. Leading world experts attempt to define its mechanism of action, and the current role of other non-surgical treatments in biliary disease. The physiology and pathogenesis of cholestatic and alcoholic liver disease and cholesterol gallstone disease is also examined.

Hepatobiliary medicine has seen major recent scientific advances in viral hepatitis, haemochromatosis and autoimmune liver/disease helped by imaging advances in MRI and CT. This volume of some 200 cases by an internationally renowned author team, covers the whole spectrum of liver disease, focusing on the clinical photos, imaging, charts and graphs. The problem-oriented, randomized self-assessment format, lends itself to revision and continuing professional development. The book will appeal particularly to young doctors preparing for membership and board examinations.

The scope of the book is very broad, covering a wide range of areas in HBV/HDV and HCV research, including both basic and clinical science. The selected topics range from epidemiology, immunology, molecular virology and oncology, to clinical therapy.Chronic Hepatitis B and C consists of 14 chapters, each being a review of a special topic on HBV or HCV. While review articles on a special topic can be found in periodical journals, they tend to be more restricted in presentation. Therefore, this book will provide more in-depth coverage of what are presented as "unpublished results" and "data not shown" in journal articles. Furthermore, several authors in this book do not write review articles regularly. Some authors wrote reviews on a specific topic regularly, but they tried a new topic in this book (e.g., Dr. YF Liaw on "natural course," Dr. Shih on "virion release," Dr. Michael Lai on "lymphotropism of HCV," etc. ). Overall, the book will offer useful information at the cutting age.Sample Chapter(s)

Primary sclerosing cholangitis is a chronic disease of the intra- and extrahepatic bile ducts leading to obstructions and dilatations followed by liver cirrhosis and in some cases cholangiocarcinoma. In 50% of cases primary sclerosing cholangitis is associated with inflammatory bowel disease. The cause of the disease is unknown and many questions concerning the pathogenesis still remain open. In recent years our knowledge of the natural course, the risk of cholangiocarcinoma and the possibility of medical, endoscopic and surgical treatment has increased. Ursodeoxycholic acid, endoscopic treatment and liver transplantation have become standard therapeutic procedures. This book is the proceedings of the Falk Workshop held on October 3, 1997, in Freiburg, Germany (Part II of the Liver Week Freiburg 1997), and covers the most important aspects of this fascinating disease.

Inflammation and cancer are two major disorders that cause huge concerns in our society. However, what one may not know is that both diseases are closely associated and, in particular, both occur in the gastrointestinal tract and liver. This book describes the mechanics of how inflammation can progress to cancer in these organs. The authors in this book comprehensively discuss the different biomarkers for early diagnosis, and current therapeutic treatments for these diseases. All of these would allow us to better understand the pathogenesis of both diseases. As such, this book provides comprehensive information concerning the interrelationship between inflammation and cancer in a cohesive manner, and the information derived would benefit not only basic scientists but also clinicians who are working in these fields.

Get the authoritative, up-to-date information you need on liver disease from the 7th Edition of the most trusted reference worldwide. Covering both basic science and recent clinical developments, this revised edition by Drs. Arun J. Sanyal, Thomas D. Boyer, Norah A. Terrault, and Keith D. Lindor, provides an in-depth, comprehensive look at the pathophysiology, diagnostic, and treatment information related to the liver. More than 1,100 figures and tables, many new and in full color, highlight completely updated content throughout. Expert, international authorship and comprehensive, easy-to-access information makes this edition the gold standard in the field of hepatology. Expert ConsultT eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, videos, and references from the book on a variety of devices. Includes new information on the rapid changes in treatment paradigms for acute liver failure, the latest treatments for primary biliary cholangitis, full coverage of the gut microbiome and its role in liver disease, the newest developments in drug-induced liver injury, and changes in hepatitis C virus treatment and hot-button concerns about access to care. New summary boxes at the end of each chapter and a newly streamlined table of contents make it easier to find and understand the information you're looking for. Hundreds of brand-new illustrations clearly present key aspects of liver disease.

From embryology to epidemiology, pathophysiology, diagnosis, complications, treatment and prognosis, this book provides a comprehensive overview and the latest evidence-based data on pancreaticobiliary maljunction (PBM), a congenital malformation in which the pancreatic and bile ducts join anatomically outside the duodenal wall. Resulting in various pathologic conditions, such as biliary cancer and pancreatitis, immediate prophylactic surgery is recommended upon diagnosis. The standard operative procedure for congenital biliary dilatation (CBD) is extrahepatic bile duct resection with bilioenteric anastomosis, but the optimal treatment of adult patients with PBM without biliary dilatation remains highly debatable. This book, written by pioneering editors and authors provides latest data, sheds new light on the disease. With abundant figures to aid understanding, Pancreaticobiliary Maljunction and Congenital Biliary Dilatation appeals to a wide readership, especially adult and pediatric surgeons, physicians including gastroenterologists and endoscopists, as well as radiologists and pathologists.

The regenerative capacity of the liver has been recognized for centuries, but when it is overwhelmed by insulting stimuli or is chronically damaged, its regenerative capability is substantially reduced or lost. Researchers have been working to find solutions to cure failing human liver function. Given the ability of stem cells to self- renew and differentiate into specialized cell liver types, they represent an attractive strategy to replace lost liver function. This book begins by outlining the complex nature of human liver disease and proceeds to examine the potential that stem cell-based approaches have to offer.

Prometheus was punished by the supreme god Zeus for giving to mankind the Olympic fire with which they learned to think and feel. He was chained to a cliff in the Caucasus, where, to make matters worse, he was visited daily by an eagle who ate part of his liver. At night, however, his liver grew back. We now know that the liver can regenerate, but were the ancient Greeks aware of this quality? The myth of Prometheus has been a source of inspiration for many visual artists over the centuries. In this book, the medical history of the liver is traced through the ages through an examination of historical texts on the organ's functions and properties, parallel to the art movements in which the fascinating iconography of Prometheus is reviewed. The book offers a surprising interplay of art and medicine, placing emphasis on the unique morphology of the liver.

This text provides a comprehensive review of ERCP and EUS and the clinical conditions for which they are employed. Presented in a case-based format with accompanying videos, it will serve as a valuable practical clinical resource for gastroenterologists with an interest in ERCP and EUS. The text highlights major techniques involved in ERCP, reviews complications and recent data on preventing post-ERCP pancreatitis, and discusses important issues in training in ERCP including use of endoscopic simulators and assessment of competency as emphasized in the new ACGME guidelines. For biliary diseases, new techniques for managing biliary stones, novel technologies for diagnosing indeterminate biliary strictures, and new devices for treating benign and malignant strictures are also highlighted. For pancreatic diseases, advances in minimally invasive endoscopic techniques for pancreatic stones and strictures, and management of the complications of pancreatitis are reviewed. Furthermore, ERCP is not limited by age, pregnancy or history of abdominal surgeries and special considerations particular to these patient populations are also discussed. The EUS chapters review the breadth of equipment available for performing EUS and EUS-FNA, detail the technique of performing EUS-FNA, and explore pertinent issues with training and assessing competency analogous to ERCP training. Valuable insights on the basics of cytopathology relevant to the endosonographer are summarized. The classic indication for EUS of staging luminal cancers is examined in detail while pancreaticobiliary indications are discussed highlighting newer adjunctive technologies including elastography and contrast-enhanced EUS. Although in its infancy, the brave new world of therapeutic EUS is explored with a focus on endoscopic necrosectomy, EUS-guided biliary and pancreatic access as well as the exciting possibilities of EUS-guided radiofrequency ablation and injection of anti-tumor agents. ERCP and EUS: A Case Based Approach will serve as a very useful resource for physicians who perform or refer patients for ERCP and EUS. It provides a concise yet comprehensive summary of the current status of ERCP and EUS that will help guide patient management and stimulate clinical research.

Dr. Lefkowitch is one the most well known experts on liver pathology and has updated the topic since it last published over 5 years ago. Important topics updated include benign liver tumor, vascular disorders of the liver, autoimmune hepatitis, and non-alcoholic fatty liver disease. Special emphasis is given to articles devoted to immunochemistry in liver tumors, hepatic granulomas, and diagnostic pitfalls in liver transplantation.

Gastrointestinal endoscopy plays an essential role in the management of patients with liver disease. This issue reviews the standard of care in the endoscopic management of portal hypertension and biliary disease before and after liver transplantation. A thorough knowledge of the available endoscopic diagnostic and therapeutic methods is essential for the practicing hepatologist. Emphasis is placed on recent advances in imaging techniques such as the application of capsule endoscopy and endoscopic ultrasound in the evaluation of portal hypertension and recent advances in cholangioscopy and biliary tissue sampling. Additionally new information regarding the endoscopic management of esophageal and gastric varices is reviewed. Finally, the current role of ERCP in the diagnosis and staging of cholangiocarcinoma before liver transplantation and the endoscopic management of biliary complications after liver transplantation is discussed.

A recent Institute of Medicine report has concluded that "there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs." It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska; Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology; Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B; Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B; Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents; Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment-- the most dreadful outcome of this disease; Dr. Paul Martin discusses management of end- stage chronic hepatitis B -anti-viral therapy, montherapy vs combo.therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection; Dr. Tram Tran discuss the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents-- an area with significant lack of good clinical evidence; Dr. Steve Han discuss management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection; Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma; and finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease.